On the part of the organs of vision: visual disturbances. On the part of the cardiovascular system: orthostatic hypotension. With digestive system: vomiting, dry mouth, anorexia. The anavar cycle liver and hepatobiliary disorders: changes in laboratory parameters of liver function. For the skin: skin rash, pruritus, ecchymosis, angioedema, sweating.From the Musculoskeletal System: arthralgia, myalgia. Reproductive system: galactorrhea, impotence, abnormal ejaculation , anorgasmia. From the urinary system: urinary retention. On the part of the body as a whole: insomnia, dizziness, drowsiness, anaphylactic reactions.
Also, after prolonged use Tsipraleksom abrupt discontinuation of therapy in some patients may result in a withdrawal reaction. In a dramatic admission of escitalopram may experience adverse reactions such as dizziness, headaches and nausea, the severity of which is small, and the duration – limited. To avoid cancellation of the reactions is recommended a gradual withdrawal of the drug for 1-2 weeks.
Symptoms. Dizziness, tremor, agitation, somnolence, dizziness, seizures, tachycardia, changes , arrhythmias, depression of respiratory activity, vomiting, rhabdomyolysis, metabolic acidosis, hypokalaemia. Treatment . no specific antidote. Treatment is symptomatic and supportive: gastric lavage, adequate oxygenation.Monitoring the function of the cardiovascular and respiratory systems.
INTERACTION WITH OTHER DRUGS
Pharmacodynamic interaction inhibitors may experience serious adverse reactions while taking and inhibitors as well as at the beginning of the reception of anavar cycle inhibitors sick shortly before stop taking . In such cases, serotonin syndrome may develop.
Serotonergic drugs combined use of serotonergic medication (eg tramadol, sumatriptan and other triptans) may lead to serotonin syndrome. Medical drugs that reduce the seizure threshold may lower the seizure threshold. It requires caution while with Tsipraleksom appointment of other drugs that reduce the seizure threshold (tricyclic antidepressants, antipsychotics – phenothiazines, thioxanthenes and butyrophenones – mefloquine and tramadol). Lithium, tryptophan Since the reported cases enhance the action with a joint appointment Tsipraleksa and lithium or tryptophan, caution is advised with concomitant administration of these drugs. St. John’s Wort Co-administration Tsipraleksa and products containing St. John’s wort anavar cycle (of Hypericum perforatum) , may lead to an increase in side effects. Anticoagulants and drugs affecting blood clotting blood clotting may occur with concomitant administration escitalopram with oral anticoagulants and drugs that affect blood clotting (eg, atypical antipsychotics and phenothiazines, the majority of tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory drugs, ticlopidine and dipyridamole). In such cases, when the beginning or end of escitalopram therapy requires careful monitoring of blood clotting. Alcohol Escitalopram does not take alcohol in pharmacodynamic or pharmacokinetic interaction. However, as is the case with other psychotropic drugs, the simultaneous use of escitalopram and alcohol is not recommended.
Pharmacokinetic interaction influence of other drugs on the pharmacokinetics of escitalopram. Simultaneous use of escitalopram and omeprazole 30 mg once daily results in moderate (about 50%) increase escitalopram concentration in blood plasma. Simultaneous acquisition of escitalopram and cimetidine at a dose of 400 mg twice a day anavar cycle leads to an increase (approximately 70%) escitalopram plasma concentration. Thus, it should be used with caution escitalopram simultaneously with inhibitors of cytochrome (eg, omeprazole, ezomeprozolom, fluvoxamine, lansoprazole, ticlopidine) and cimetidine. At the same time taking escitalopram and the aforementioned drugs based on monitoring of side effects may require dose reduction of escitalopram.